How MBG453 works
T-cells are crucial to the immune system performing its normal function of attacking and destroying cancer cells.
TIM-3 is an immune checkpoint, or protein that ensures that the immune system does not mistakenly attack healthy cells. Tumor cells have found a way to use checkpoints to prevent the immune system from attacking and destroying them. They apply a brake to the system to stop its normal functioning, including attacking cancer.
MBG453 binds to TIM-3 on the surface of T-cells, releasing the brakes that the tumor applied to the immune system. This allows it to function normally against cancer cells, reducing tumor growth.
MBG453 in clinical trials
Novartis is conducting Phase 1/2 clinical trials of MBB453 as a treatment for several types of cancer.
A Phase 1/2 trial (NCT02608268) is investigating the safety and effectiveness of MBG453, either alone or combined with another immunotherapy, in patients with solid tumors. The PDR001 study started in November 2015. It continues to recruit participants in the United States, Canada, Japan, Europe, China, and Singapore.
Novartis started another Phase 1 trial (NCT03066648) in July 2017. It is studying the safety of a combination of MBG453 and the chemotherapy Dacogen (decitabine) in patients with hematologic cancers, and patients’ ability to tolerate the treatment. One goal of the trial is to identify recommended doses for future studies. Researchers are recruiting participants in the United Kingdom, Spain and Australia.
Immuno-Oncology News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.